Ticker
JNJ

Price
167.13
Stock movement up
+1.55 (0.94%)
Company name
Johnson & Johnson
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
439.79B
Ent value
-
Price/Sales
4.60
Price/Book
-
Div yield
2.70%
Div growth
5.87%
Growth years
58
FCF payout
70.56%
Trailing P/E
23.95
Forward P/E
15.49
PEG
3.74
EPS growth
-0.30%
1 year return
-4.08%
3 year return
9.36%
5 year return
4.71%
10 year return
9.46%
Last updated: 2022-08-25

BUSINESS INSIGHT

Segment Revenues ($M)

Loading...

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share4.52
Dividend yield2.70%
Payout frequencyQuarterly
Maximum yield3.64%
Average yield2.66%
Minimum yield2.27%
Discount to avg yield1.49%
Upside potential1.52%
Yield as % of max yield74.40%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield2.70%
Current yield distribution41.35%
Yield at 100% (Min)2.27%
Yield at 90%2.46%
Yield at 80%2.52%
Yield at 50% (Median)2.66%
Yield at 20%2.81%
Yield at 10%2.90%
Yield at 0% (Max)3.64%

Dividend per share

Loading...
Dividend per share data
Years of growth58 years
CCC statusDividend Champion
Dividend per share4.52
Payout frequencyQuarterly
Ex-div date22 Aug 2022
EPS (TTM)9.88
EPS (1y forward)10.79
EPS growth (5y)-0.30%
EPS growth (5y forward)6.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
JNJS&P500
DGR MR6.60%15.44%
DGR TTM5.80%7.80%
DGR 3 years5.78%3.88%
DGR 5 years5.87%4.73%
DGR 10 years6.42%8.30%
DGR 15 years7.31%5.82%
Time since last change announced166 days
EPS growth (5y)-0.30%
EPS growth (5y forward)6.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM45.57%70.56%
Average--
Forward41.89%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E23.95
Price to OCF24.43
Price to FCF37.08
Price to EBITDA35.40
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.60
Price to Book-
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count2.63B
EPS (TTM)9.88
FCF per share (TTM)6.38

Income statement

Loading...
Income statement data
Revenue (TTM)95.59B
Gross profit (TTM)64.87B
Operating income (TTM)24.24B
Net income (TTM)18.37B
EPS (TTM)9.88
EPS (1y forward)10.79

Margins

Loading...
Margins data
Gross margin (TTM)67.86%
Operating margin (TTM)25.36%
Profit margin (TTM)19.21%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash0.00
Net receivables0.00
Total current assets0.00
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets0.00
Accounts payable0.00
Short/Current long term debt0.00
Total current liabilities0.00
Total liabilities0.00
Shareholder's equity0.00
Net tangible assets-4.65B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)18.00B
Capital expenditures (TTM)2.77B
Free cash flow (TTM)11.86B
Dividends paid (TTM)8.37B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open165.95
Daily high167.24
Daily low164.70
Daily Volume4.57M
All-time high186.01
1y analyst estimate188.11
Beta0.63
EPS (TTM)9.88
Dividend per share4.52
Ex-div date22 Aug 2022
Next earnings date18 Oct 2022

Downside potential

Loading...
Downside potential data
JNJS&P500
Current price drop from All-time high-10.15%-12.18%
Highest price drop-38.78%-56.47%
Date of highest drop11 Aug 19939 Mar 2009
Avg drop from high-9.39%-11.38%
Avg time to new high19 days12 days
Max time to new high1038 days1805 days
COMPANY DETAILS
JNJ (Johnson & Johnson) company logo
Marketcap
439.79B
Marketcap category
Large-cap
Description
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Employees
141700
SEC filings
CEO
Alex Gorsky
Country
USA
City
New Brunswick
Stock type
Common stock
CCC status
Dividend Champion
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Over the past 20 years, medical device giant Intuitive Surgical (NASDAQ: ISRG) has substantially outperformed the market. In fact, over the next couple of decades, Intuitive Surgical has a shot at be...
September 30, 2022
Dividends are a popular wealth-building tool, but let's face it: A dividend is only as helpful as it is reliable. Chasing stocks because they have high dividend yields is a dangerous game; sometimes,...
September 30, 2022
The healthcare giant has been a fairly stable investment this year, but does it belong in your portfolio for the long term?
September 29, 2022
Aligos Therapeutics Inc (NASDAQ: ALGS) has filed a response to the complaint of and counterclaims against Janssen Biopharma. In November 2014, Johnson & Johnson (NYSE: JNJ) acquired Alios BioPharma In...
September 29, 2022
The factors keeping ARK Invest's boss away might actually be reasons to buy, depending on your needs.
September 29, 2022
You might be living under a rock if you haven't heard the word "recession" being thrown around in the media over the past few months. Thanks to inflation, the Federal Reserve's efforts to control inf...
September 28, 2022
Johnson & Johnson named its consumer business Kenvue on Wednesday, moving ahead with its plans to spin-off the unit in what would be the biggest shake-up in the healthcare conglomerate's 135-year hist...
September 28, 2022
Johnson & Johnson's planned new consumer health company will be named Kenvue, the healthcare conglomerate said on Wednesday. Johnson & Johnson said last year it planned to spin off its consumer busin...
September 28, 2022
NEW BRUNSWICK, N.J., September 28, 2022--Johnson & Johnson (the "Company") (NYSE: JNJ) today took another step forward in establishing two independent, market-leading companies with the announcement o...
September 28, 2022
We’re in the midst of a bear market. That’s something investors haven’t seen in quite some time. While many stocks are getting crushed, it does create an opportunity for patient buyers, especially wit...
September 27, 2022
Next page